财务数据和关键指标变化 - 公司实现收入3.152亿美元,同比下降0.8% [24] - 归属普通股东净亏损1770万美元,每股亏损0.22美元,同比增加 [25] - 调整后EBITDA1280万美元,同比增长 [26] 各条业务线数据和关键指标变化 基础设施业务 - 收入3.079亿美元,同比下降1.2% [26] - 调整后EBITDA1830万美元,同比增长 [27] - 在手订单939.1百万美元,调整后在手订单12亿美元 [28] - 债务减少3910万美元,过去6个月减少7300万美元 [29] 生命科学业务 - 收入100万美元,同比增长50% [30] - 调整后EBITDA亏损减少,主要由于MediBeacon投资亏损减少和R2费用下降 [30] 频谱业务 - 收入6300万美元,同比增长9.5% [31] - 调整后EBITDA160万美元,同比增长 [32] 公司战略和发展方向及行业竞争 - 基础设施业务在工业和模块化领域有众多机会,将成为未来重要业务 [9] - 生命科学业务R2在北美系统销售增长183%,在中东地区也有新的发展 [10][11] - MediBeacon肾功能监测项目正在与FDA互动解决问题,以推进审批 [13][14] - 频谱业务新网络推出带动收入增长,并探索5G广播等新技术机会 [17][19] 管理层对经营环境和未来前景的评论 - 基础设施业务市场环境仍然紧张,但新项目活动旺盛 [9] - 生命科学业务R2增长势头良好,MediBeacon有望获批 [10][11][13][14] - 频谱业务新网络推出和新技术探索为未来带来机遇 [17][19] - 公司正在采取措施优化资本结构,为未来发展创造条件 [20][21][22] 其他重要信息 - 公司未能符合纽交所最低股价要求,正在采取措施如反向拆股等来恢复合规 [35] - 公司总债务6.87亿美元,较年末下降3580万美元 [36]

INNOVATE Corp. Q1 2024 Earnings Release Supplement May 7, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 INNOVATE CORP. (Exact name of registrant as specified in its charter) Delaware 54-1708481 (State or other jurisdiction of (I.R.S. Employer incorporation or organization ...

财务表现 - INNOVATE Corp.宣布2024年第一季度财报，总收入为3.152亿美元，较去年同期下降0.8%[2] - Infrastructure部门DBM Global Inc.在2024年第一季度实现了3.079亿美元的营收，同比增长1.2%[4] - Spectrum部门2024年第一季度营收为630万美元，较去年同期增长[8] 公司业绩 - DBM Global的毛利率在第一季度达到14.6%，较去年同期扩大约150个基点[5] - R2 Technologies在北美创下销售系统和患者治疗次数的记录，全球发货超过400套系统[7] 财务状况 - INNOVATE Corp.第一季度净亏损为1770万美元，较去年同期增加[9] - Adjusted EBITDA在2024年第一季度达到1280万美元，较去年同期增长161.2%[10] 公司会议 - INNOVATE将于当天下午4:30举行电话会议讨论2024年第一季度财报和运营情况[11] - 公司网站innovate-ir.com提供会议直播和回放的链接[12] 财务比较 - INNOVATE Corp. 2024年第一季度营收为315.2百万美元，较2023年同期的317.9百万美元略有下降[23] - INNOVATE Corp. 2024年第一季度净亏损为17.7百万美元，较2023年同期的10.2百万美元有所增加[23] - INNOVATE Corp. 2024年第一季度现金及现金等价物为38.4百万美元，较2023年底的80.8百万美元有显著减少[24] - INNOVATE Corp. 2024年第一季度调整后EBITDA为12.8百万美元，较2023年同期的4.9百万美元有所增加[25]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 INNOVATE CORP. (Exact name of registrant as specified in its charter) Delaware 54-1708481 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Ide ...

INNOVATE Corp. (NYSE:VATE) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Anthony Rozmus - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chief Financial Officer Operator Good afternoon, and welcome to INNOVATE Corp.'s Fourth Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. After prepared remarks and presentation, there will be a question-and-answer session. Please note, this event is being recorded. I would n ...

FOR IMMEDIATE RELEASE INNOVATE Corp. Announces Fourth Quarter and Full Year 2023 Results - Infrastructure: DBM Global achieved fourth quarter revenue of $353.8 million - - Life Sciences: R2 experienced strong North America unit sales in the fourth quarter - - Spectrum: Broadcasting entered into agreements with PBS stations for new commercial opportunities with ATSC 3.0 - NEW YORK, NY, March 4, 2024 - INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the f ...

INNOVATE Corp. Q4 2023 Earnings Release Supplement March 4, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 INNOVATE CORP. (Exact name of registrant as specified in its charter) Delaware 54-1708481 (State or other jurisdiction of (I.R.S. Employer incorporation or organiza ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 INNOVATE CORP. (Exact name of registrant as specified in its charter) Delaware 54-1708481 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) ...